Dose verification system
|This article relies too much on references to primary sources. (June 2008)|
DVS (Dose Verification System), developed by Sicel Technologies, is an implantable telemetric, radiation sensor that has been cleared for use by the U.S. Food & Drug Administration (FDA) in the treatment of breast cancer and prostate cancer.
The device is used to measure the amount of radiation that is delivered to the tumor tissue, tumor bed and/or healthy tissue. The DVS sensor contains a dosimeter and wireless transmitter inside a sealed, biocompatible glass capsule measuring 0.8 inches (20mm) long and 0.08 inches (2.1mm) across.
The DVS sensors are implanted during a minimally invasive procedure prior to starting radiation therapy. The sensor is placed 3 cm beneath the surface of the skin to ensure adequate build-up, especially at higher energies and to maintain a consistent temperature.
Before and after each treatment, a radiation therapist will use a hand-held reader held above the skin near the dosimeter to transmit and report dosage information immediately to the radiation oncology team. The information alerts the team to random or systematic deviations from the prescribed dose that can have a profound impact on tumor control and surrounding normal tissue.
After Radiation Treatment
At the conclusion of radiation treatment, the DVS sensor remains in the body permanently but has no impact on everyday life. The sensors are compatible with medical procedures such as mammography and MRI therefore it important to tell all healthcare providers about DVS. During a monthly breast self-exam it is possible that a person may be able to feel the dosimeter, so it is also important to note the location when it is implanted.